Drug Approval | December 13, 2022
European Commission approves SPEVIGO for generalized pustular psoriasis flares
EC grants conditional marketing authorization based on the EFFISAYIL trial
EC grants conditional marketing authorization based on the EFFISAYIL trial
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
To set up 50 lifestyle modification centres across the UAE in the next 24 months
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Biopharma and CROs to benefit from simplified access to global research sites
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Subscribe To Our Newsletter & Stay Updated
